Mipomersen REMS Would Rely on Education, Not Prescribing Restrictions, To Address Hepatotoxicity
This article was originally published in The Pink Sheet Daily
Executive Summary
REMS will include a prescription form that has prescribers attest that the prescription is medically appropriate and that they will monitor hepatotoxicity biomarkers, according to FDA and Genzyme briefing materials for an Oct. 18 Metabolic and Endocrinologic Drugs Advisory Committee.
You may also be interested in...
Panel Review Of Aegerion’s Lomitapide May Lead To Evolution Of Cholesterol Drug Approval Standards
FDA will be using an upcoming advisory panel review of Aegerion Pharmaceuticals Inc.’s lomitapide to see if there is still support for traditional lipid endpoints in clinical trials of cholesterol drugs.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.